On the other hand, nivolumab clearly promoted an enrichment in CD45+ immune infiltrates in colorectal cancer ALI-PDOs (Figure 6G), which was especially driven by CD3+T cells (Figure 6H). Here, PTPRC is linked to colorectal cancer.